Introducing the next Regional Federation - Americas. Regional federations help IAS by strengthening relationships & collaborations with IAS members and facilitating new relationships between IAS and relevant organizations with similar objectives. This group of doctors is working to further IAS's mission to advance #atherosclerosis care in the Americas region. #MeetTheRFMondays #CollaborateForImpact (fb)

During "The Challenge to Primary Prevention" webinar, many of you submitted great questions to the panel, and Peter Libby, MD, has provided answers to some of them in IAS' new digital segment: #AskTheExpert! 𝗛𝗼𝘄 𝗰𝗮𝗻 𝘄𝗲 𝗯𝗲𝘁𝘁𝗲𝗿 𝗰𝗼𝘂𝗻𝘀𝗲𝗹 𝗹𝗼𝘄-𝗿𝗶𝘀𝗸 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗼𝗻 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝘀𝘁𝗮𝘁𝗶𝗻 𝘂𝘀𝗲, 𝗲𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗹𝘆 𝘄𝗵𝗲𝗻 𝗟𝗗𝗟 𝗶𝘀 𝗵𝗶𝗴𝗵 𝗯𝘂𝘁 𝗔𝗦𝗖𝗩𝗗 𝗿𝗶𝘀𝗸 𝗶𝘀 𝗹𝗼𝘄? 𝘠𝘰𝘶 𝘮𝘢𝘺 𝘦𝘹𝘱𝘭𝘢𝘪𝘯 𝘵𝘰 𝘵𝘩𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘵𝘩𝘢𝘵 𝘳𝘪𝘴𝘬 𝘤𝘢𝘭𝘤𝘶𝘭𝘢𝘵𝘰𝘳𝘴 𝘨𝘦𝘯𝘦𝘳𝘢𝘭𝘭𝘺 𝘤𝘰𝘮𝘱𝘶𝘵𝘦 𝘰𝘯𝘭𝘺 10-𝘺𝘦𝘢𝘳 𝘳𝘪𝘴𝘬 𝘸𝘩𝘪𝘭𝘦 𝘺𝘰𝘶 𝘢𝘳𝘦 𝘤𝘰𝘯𝘤𝘦𝘳𝘯𝘦𝘥 𝘢𝘣𝘰𝘶𝘵 𝘵𝘩𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵'𝘴 𝘭𝘪𝘧𝘦𝘵𝘪𝘮𝘦 𝘳𝘪𝘴𝘬, 𝘢𝘯𝘥 𝘰𝘶𝘳 𝘣𝘦𝘴𝘵 𝘦𝘷𝘪𝘥𝘦𝘯𝘤𝘦 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘴 𝘵𝘩𝘢𝘵 𝘭𝘰𝘸𝘦𝘳𝘪𝘯𝘨 𝘓𝘋𝘓 𝘦𝘷𝘦𝘯 𝘦𝘢𝘳𝘭𝘺 𝘤𝘢𝘯 𝘪𝘮𝘱𝘳𝘰𝘷𝘦 𝘭𝘰𝘯𝘨-𝘵𝘦𝘳𝘮 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴 𝗜𝗳 𝗹𝗶𝗽𝗼𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗿𝗶𝘀𝗸 𝗶𝘀 𝗮𝗻 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗰𝗮𝘂𝘀𝗮𝗹 𝗱𝗿𝗶𝘃𝗲𝗿 𝗼𝗳 𝗱𝗶𝘀𝗲𝗮𝘀𝗲...𝗪𝗵𝘆 𝗻𝗼𝘁 𝘂𝘀𝗲 𝗮𝗽𝗼𝗕 - 𝗮𝗻 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗺𝗲𝗮𝘀𝘂𝗿𝗲 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗯𝘂𝗿𝗱𝗲𝗻 - 𝘄𝗵𝗲𝗻 𝗔𝗽𝗼𝗕 𝗮𝗻𝗱 𝗟𝗗𝗟-𝗖/𝗻𝗼𝗻-𝗛𝗗𝗟-𝗖 𝗱𝗶𝘀𝗮𝗴𝗿𝗲𝗲 𝗶𝗻 𝗮 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗺𝗶𝗻𝗼𝗿𝗶𝘁𝘆? 𝘐𝘯 𝘱𝘳𝘢𝘤𝘵𝘪𝘤𝘦 𝘴𝘦𝘵𝘵𝘪𝘯𝘨𝘴 𝘸𝘩𝘦𝘳𝘦 𝘢𝘱𝘰𝘭𝘪𝘱𝘰𝘱𝘳𝘰𝘵𝘦𝘪𝘯 𝘉 𝘮𝘦𝘢𝘴𝘶𝘳𝘦𝘮𝘦𝘯𝘵𝘴 𝘢𝘳𝘦 𝘳𝘦𝘢𝘥𝘪𝘭𝘺 𝘢𝘤𝘤𝘦𝘴𝘴𝘪𝘣𝘭𝘦, 𝘪𝘵 𝘤𝘢𝘯 𝘣𝘦 𝘢 𝘶𝘴𝘦𝘧𝘶𝘭 𝘢𝘥𝘫𝘶𝘯𝘤𝘵 𝘵𝘰 𝘤𝘢𝘭𝘤𝘶𝘭𝘢𝘵𝘦𝘥 𝘓𝘋𝘓, 𝘣𝘶𝘵 𝘱𝘳𝘢𝘤𝘵𝘪𝘤𝘢𝘭𝘭𝘺, 𝘯𝘰𝘯 𝘏𝘋𝘓 𝘤𝘩𝘰𝘭𝘦𝘴𝘵𝘦𝘳𝘰𝘭 𝘤𝘢𝘯 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘷𝘦𝘳𝘺 𝘴𝘪𝘮𝘪𝘭𝘢𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯. Watch webinar recording to learn more: https://bit.ly/4kvmLbG (fb)